BioTime, Inc. (BTX) Starts Presentation at LD Micro Main Event
BioTime, Inc. (NYSE: BTX) is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. BioTime’s pipeline is based on two platform technologies which encompass cell replacement and cell/drug delivery. BioTime’s lead cell replacement product candidate is OpRegen, a retinal pigment epithelium transplant therapy in Phase 2 development for the treatment of dry age-related macular degeneration, the leading cause of blindness in the developed world. BioTime’s lead cell delivery clinical program is Renevia, an investigational medical device being developed as an alternative for whole adipose tissue transfer procedures. For more information,…